Pridopidine for ALS Treatment
Summary
USPTO published patent application US20260091028A1 by Prilenia Neurotherapeutics Ltd. for a method of treating amyotrophic lateral sclerosis (ALS) using pridopidine. The application claims therapeutic use of pridopidine or a pharmaceutically acceptable salt for human subjects afflicted with ALS. Application No. 19391284 was filed on 2025-11-17.
What changed
USPTO published patent application US20260091028A1 (Kind A1) assigned to Prilenia Neurotherapeutics Ltd. The application claims a method for treating ALS in human subjects by administering a therapeutically effective amount of pridopidine. Inventors are Michael Hayden and Michal Geva. The application falls under CPC classifications including A61K 31/451, A61P 25/28 (nervous system diseases).
This is a routine patent application publication that provides public notice of the claimed invention. Competitors developing ALS treatments should review the claims to assess potential freedom-to-operate implications. The patent, if granted, would provide Prilenia with exclusionary rights to the claimed ALS treatment method. Pharmaceutical companies with competing ALS programs should monitor prosecution of this application for claim scope and potential licensing opportunities.
What to do next
- Review patent claims for freedom-to-operate analysis if developing competing ALS treatments
- Monitor prosecution of this application for claim scope and amendments
- Assess potential licensing or cross-licensing opportunities if claims overlap with development programs
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE
Application US20260091028A1 Kind: A1 Apr 02, 2026
Assignee
PRILENIA NEUROTHERAPEUTICS LTD.
Inventors
Michael HAYDEN, Michal GEVA
Abstract
Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine or pharmaceutically acceptable salt thereof.
CPC Classifications
A61K 31/451 A61K 9/4825 A61K 31/192 A61K 31/4152 A61K 31/4245 A61K 31/428 A61K 31/439 A61K 31/485 A61K 31/575 A61K 31/661 A61K 31/7016 A61K 33/242 A61P 25/28
Filing Date
2025-11-17
Application No.
19391284
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.